Skip to content
Home/About us/Meet our leadership team/Blogs/Harnessing Data to Shape the Future of Regulatory Affairs

Harnessing data to shape the future of regulatory affairs

Share Article
Share to

As the complexity of our global healthcare environment increases, the significance of integrating novel strategies to address today’s regulatory challenges is a top priority. With Janssen Research & Development, LLC, Global Regulatory Affairs (GRA) – an organization of approximately 900 high-qualified regulatory experts – is shaping the future regulatory pathway by utilizing approaches to adapt within an ever-evolving health care environment, while remaining focused on the needs of patients, health care professionals and caregivers around the world.

One of the driving forces behind the innovative problem-solving efforts with Janssen GRA is a newly established Data Science team that will focus on advancing the use of real-world evidence data, digital data sources and tools, modeling and simulation, and clinical trial innovation, in addition to an emphasis on enhancing regulatory operation processes.

Driving Regulatory Innovation at DIA 2019

I’m excited these and other important topics will be covered at the DIA 2019 Annual Global Meeting, a conference bringing together thousands of innovators to focus on efforts to influence action on critical policy discussions and bring new insights and developments to the public sphere. Janssen’s GRA team has a large presence at this year’s conference (June 23-27), reflecting our expertise and commitment in drug policy innovation. I am encouraged by the presence of my colleagues in San Diego as they share insights on a number of key focus areas for regulatory affairs, including career development, pediatric policy, starting material designation, gene therapy, digital technology and real world data quality.

See a full listing below for what to expect from the Janssen GRA team, and links for more details on each session:

* Developed with Karen Weiss, MD, MPH, VP GRPI

I’m very proud of these colleagues for sharing their expertise on these topics. We understand the long-term commitment to building a brighter tomorrow and look forward to using a data science platform to work towards solving problems, creating evidence for regulatory review, driving efficiencies and discovering insights.

Afterall, “a journey of a thousand miles begins with a single step.” – Chinese Proverb

Karin Van Baelen, PharmD
Karin Van Baelen, PharmD
Karin Van Baelen, PharmD
Karin Van Baelen, PharmD, is Head of Global Regulatory Affairs at Janssen Research & Development, LLC. In this role, Karin facilitates the relationship between Janssen and global health authorities, ensuring high-quality and on-time regulatory submissions and approvals of products from all therapeutic areas.